Early research (Phase 1)Study completedNCT00004047What this trial is testingChemotherapy in Treating Patients Who Have Hematologic CancerWho this might be right forLeukemiaMyelodysplastic Syndromes Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00365287What this trial is testingCombination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerWho this might be right forBreast CancerKidney CancerLeukemia+3 more Masonic Cancer Center, University of Minnesota 148
Early research (Phase 1)Study completedNCT01729806What this trial is testingIpilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaWho this might be right forCD20 PositiveRecurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Ended earlyNCT00511043What this trial is testingPTK787 in Refractory or Relapsed Diffuse Large Cell LymphomaWho this might be right forLymphoma, Large-Cell, Diffuse David Rizzieri, MD 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT02952508What this trial is testingStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromWho this might be right forWaldenstrom MacroglobulinemiaMultiple MyelomaChronic Lymphocytic Leukemia+6 more Cellectar Biosciences, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT01261247What this trial is testingPanobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWho this might be right forAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+18 more Mayo Clinic 41
Testing effectiveness (Phase 2)Study completedNCT03575325What this trial is testingVyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic LeukemiaWho this might be right forLymphoid LeukemiaAcute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia+1 more H. Lee Moffitt Cancer Center and Research Institute 11
Testing effectiveness (Phase 2)Study completedNCT02038933What this trial is testingStudy of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)Who this might be right forLymphoma. Non-Hodgkin Bristol-Myers Squibb 121
Testing effectiveness (Phase 2)Study completedNCT00918333What this trial is testingPanobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaWho this might be right forAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+25 more Mayo Clinic 124
Early research (Phase 1)Not Yet RecruitingNCT07511426What this trial is testingU96-CAR-T-Cells For R/R B-ALLWho this might be right forRelapsed or Refractory B Cell Leukemia and Lymphoma The First Affiliated Hospital of Soochow University 30
Very early researchUnknownNCT04532268What this trial is testingHumanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLWho this might be right forAcute Lymphoblastic LeukemiaNon-hodgkin Lymphoma,B Cell Zhejiang University 72
Large-scale testing (Phase 3)Looking for participantsNCT06006117What this trial is testingMosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaWho this might be right forMarginal Zone Lymphoma The Lymphoma Academic Research Organisation 260
Testing effectiveness (Phase 2)Looking for participantsNCT06634589What this trial is testingInvestigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesWho this might be right forB-cell MalignancyRelapsed CancerRefractory Cancer+1 more BeOne Medicines 80
Early research (Phase 1)Study completedNCT00002818What this trial is testingHigh-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic MalignanciesWho this might be right forDrug/Agent Toxicity by Tissue/OrganLeukemiaLymphoma+1 more Virginia Commonwealth University 15
Early research (Phase 1)Study completedNCT00962507What this trial is testingPanobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaWho this might be right forLymphomaMultiple Myeloma and Plasma Cell Neoplasm City of Hope Medical Center 11
Early research (Phase 1)UnknownNCT03576807What this trial is testingThe Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte LymphomaWho this might be right forRelapsed or Refractory B-cell Lymphomas Xin Wang 20
Very early researchLooking for participantsNCT06446128What this trial is testingA Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)Who this might be right forNon-Hodgkin Lymphoma, B-cell Shanghai Cell Therapy Group Co.,Ltd 20
Early research (Phase 1)Study completedNCT03263637What this trial is testingStudy to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesWho this might be right forRelapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more AstraZeneca 44
Very early researchLooking for participantsNCT05800405What this trial is testingEvaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell LymphomaWho this might be right forRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma City of Hope Medical Center 9
Early research (Phase 1)Looking for participantsNCT07451054What this trial is testingCD45BE-HSPC + CART-45 CellsWho this might be right forB-Cell Non-Hodgkin Lymphoma (NHL)Richter's TransformationT-Cell Non-Hodgkin Lymphoma+1 more University of Pennsylvania 42